Liberal Use of Sodium in Ambulatory Heart Failure (LUSA-HF)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
At the start of the study, baseline investigations are performed including assessment of vital signs (blood pressure, heart rate, pulse oxygen saturation), weight, Everest congestion score (consisting of grading of dyspnea, orthopnea, jugular venous distention, rales, edema and fatigue), echocardiography, 24h urine collection, bio-impedance measurements and blood sample analysis with plasma renin and aldosterone Subsequently, a run-in phase of 2 weeks, without intervention, will start. After this run-in period, participants will be reassessed with the same baseline investigations. In addition, a skin biopsy will be performed as well as a blood volume measurement.
In the next phase of the study, salt intake will be increased with 3 grams daily. The salt will be packed in capsules containing 1 g of sodium chloride (NaCl). Patients will be asked to take one capsule with their breakfast, lunch and dinner. Every 2 weeks a follow-up visit is planned.
After 4 weeks of increased salt intake, a new skin biopsy will be taken and a blood volume measurement will be performed.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Jeroen Dauw, MD
- Phone Number: +3289212062
- Email: jeroen.dauw@zol.be
Study Contact Backup
- Name: Wilfried Mullens, MD, PhD
- Phone Number: +3289327110
- Email: wilfried.mullens@zol.be
Study Locations
-
-
-
Genk, Belgium, 3600
- Ziekenhuis Oost-Limburg
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Heart failure patients:
- Left ventricular ejection fraction ≤40% on echocardiogram obtained at inclusion
- Stable dose of guideline-recommended disease modifying drugs for at least 3 months.
- Maximum daily loop diuretic dose of 40 mg furosemide equivalents with a stable dose for the last month
Healthy volunteers:
- Age > 60 y
- Normal ejection fraction (>50%) without heart failure
- No neurohormonal blockers for hypertension
- Normal NT-proBNP
Exclusion Criteria:
- Heart failure hospitalization for congestion or myocardial infarction in past 3 months
- Permanent atrial fibrillation
- New York Heart Association (NYHA) class III-IV
- Estimated glomerular filtration rate (eGFR) < 30 mL/min
- Signs of congestion
- Severe right ventricular dysfunction
- Severe valvular disease
- Cardiothoracic anatomy not allowing satisfactory and reproducible recordings of echocardiogram
- Inability to fully comprehend and/or perform study procedures in the investigator's opinion.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Heart failure
After a run-in phase of 2 weeks, patients will add 3 g of sodium chloride to every meal, using a NaCl tablet of 1 g.
They will continue the sodium tablet for 4 weeks with a study visit every 2 weeks.
A skin biopsy will be performed before the start of the augmented salt intake and after 4 weeks.
|
1 gram tid (with every meal)
|
|
Active Comparator: Healthy volunteer
After a run-in phase of 2 weeks, volunteers will add 3 g of sodium chloride to every meal, using a NaCl tablet of 1 g.
They will continue the sodium tablet for 4 weeks with a study visit every 2 weeks.A skin biopsy will be performed before the start of the augmented salt intake and after 4 weeks.
|
1 gram tid (with every meal)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Changes in skin glycosaminoglycan (GAG) content
Time Frame: 4 weeks
|
4 weeks
|
|
Changes in skin sodium content
Time Frame: 4 weeks
|
4 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Changes in blood volume assessed by radiolabeled red blood cell technique
Time Frame: 4 weeks
|
4 weeks
|
|
Changes in extracellular, intravascular volume and total body fluid volume (assessed with bioimpedance)
Time Frame: 6 weeks
|
6 weeks
|
|
Changes in renal sodium handling
Time Frame: 6 weeks
|
6 weeks
|
|
Changes in cardiac geometry assessed by echo
Time Frame: 6 weeks
|
6 weeks
|
|
Changes in renal venous flow pattern
Time Frame: 6 weeks
|
6 weeks
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in Everest congestion score
Time Frame: 6 weeks
|
The Everest score assesses congestion, based on a point scale with a range from 0 (no congestion) to 18 (worst congestion)
|
6 weeks
|
|
Changes in weight
Time Frame: 6 weeks
|
6 weeks
|
|
|
Changes in blood pressure
Time Frame: 6 weeks
|
6 weeks
|
|
|
Changes in thirst visual analogue scale (VAS)
Time Frame: 6 weeks
|
The scale ranges from 0 -100 with 0 indicating no thirst and 100 the worst thirst.
|
6 weeks
|
|
Changes in aldosterone
Time Frame: 6 weeks
|
6 weeks
|
|
|
Changes in renin
Time Frame: 6 weeks
|
6 weeks
|
|
|
Changes in N-terminal (NT)-pro hormone BNP (NT-proBNP)
Time Frame: 6 weeks
|
NT-proBNP will be measured using Roche diagnostics assay (Mannhein, Germany) and expresed as picogram per liter
|
6 weeks
|
|
Occurrence of congestion
Time Frame: 4 weeks
|
4 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Jeroen Dauw, MD, Ziekenhuis Oost-Limburg
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ZOLCAR19001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.